Fentanyl sublingual - BTcP Pharma/Pharmbio Korea
Alternative Names: Fentanyl SL spray - INSYS Therapeutics; Fentanyl sublingual spray - INSYS Therapeutics; FSS; SubsysLatest Information Update: 31 Dec 2021
At a glance
- Originator INSYS Therapeutics, Inc
- Developer INSYS Therapeutics, Inc; M. D. Anderson Cancer Center
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cancer pain
- Discontinued Dyspnoea; Postoperative pain
Most Recent Events
- 27 Jan 2021 M.D. Anderson Cancer Center and INSYS Therapeutics completes a phase II/III trial in Dyspnoea in USA (Sublingual) (NCT02597478)
- 07 Aug 2020 M.D. Anderson Cancer Center and INSYS Therapeutics terminates phase II trial in Cancer pain in USA (Sublingual) (NCT02514252)
- 08 May 2018 Lunatus acquires licence for Fentanyl sublingual formulation from INSYS Therapeutics in Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates